

March 10, 2016
Seikagaku Corporation
(Securities Code: TSE 4548)

Seikagaku Announces a Change in Sales Partner for MucoUp[®] Surgical Aid for Endoscopic Mucosal Resection in Japan

Seikagaku Corporation (hereafter "Seikagaku") (head office: Chiyoda-ku, Tokyo) has agreed on basic terms and conditions for an exclusive distribution agreement, effective on April 1, 2016, for MucoUp[®], surgical aid for endoscopic mucosal resection (hereafter "MucoUp") in Japan with Boston Scientific Japan K.K. (head office: Nakano-ku, Tokyo). Seikagaku is the marketing authorization holder for MucoUp in Japan. Meanwhile, the term of exclusive distribution agreement with Johnson and Johnson K.K. Medical Company (head office: Chiyoda-ku, Tokyo) will expire on March 31, 2016.

MucoUp is a medical device for which the main ingredient is sodium hyaluronate. MucoUp is a user-friendly surgical aid for the formation and retention of adequate submucosal elevation at a neoplasm lesion site in the esophagus, stomach or colorectum for endoscopic mucosal resection.

Boston Scientific Endoscopy is a world leader in the development and commercialization of minimally invasive devices for gastrointestinal and pulmonary diseases, and offers a broad portfolio of devices and extensive customer support, in addition to delivering innovative solutions, to the patients with digestive and respiratory disease.

Seikagaku will support the activities of its sales partner by providing academic information as a marketing authorization holder, and Seikagaku and Boston Scientific will contribute to improve the quality of life for patients.

There will be no revision to the forecast of consolidated results for fiscal 2015 as a result of this development.

#####